Clinical Manifestations and Management of Inherited Thrombophilia: Retrospective Analysis and Follow-up after Diagnosis of 238 Patients with Congenital Deficiency of Antithrombin III, Protein C, Protein S

Summary

The clinical history of 238 patients with inherited thrombophilia (AT III = 94, PC = 103, PS = 41) was analyzed retrospectively at diagnosis and in the follow-up period after diagnosis. At diagnosis 129 patients (54%) had suffered from thrombosis, with a recurrence rate of 48%. The most frequent onset manifestation was deep vein thrombosis of lower limbs (58%). Thrombotic history started before 40 in 80% of the cases. Forty-nine percent of the venous thromboses were preceded by a triggering event, in most cases pregnancy (17%) and surgery (12%). After diagnosis, follow-up lasted a total of 1,113 pt-years. A policy of short-term prophylaxis during risk situations for all patients and long-term prophylaxis in symptomatic patients failed to prevent venous thrombotic episodes (diagnosed by objective methods) in 4 previously asymptomatic subjects and recurrence in 7 previously symptomatic subjects. After knowledge of the patients’ diagnosis the incidence of venous thrombosis/100 pt-years was reduced as compared before diagnosis as total episodes (onset + recurrencies) (1.0 vs 1.9), onset episodes (0.7 vs 1.3) and recurrent episodes (1.3 vs 4.8), even though the differences were not statistically significant. However most of the venous thromboses occurred at a more advanced age (67% after 40 years) and without any apparent cause (83%), at significant variance with the period preceding the diagnosis; in particular the incidence of venous thrombotic onset in patients younger than 40 passed from 1.3/100 pt-years to 0.2/100 pt-years. In 6 recurrences after diagnosis a poor compliance for antithrombotic treatment was recognized. We conclude that a policy based on knowledge of diagnosis and on the implementation of antithrombotic treatment during risk situations appears to modify the clinical outcome of deficiencies of natural anticoagulants even in the absence of long-term antithrombotic prophylaxis; in particular morbidity of young patients is significantly reduced.

• References

• 1 The British Committee for Standards in Haematology. Guidelines on the investigation and management of thrombophilia. J Clin Pathol 1990; 43: 703-709
• 2 Demers C, Ginsberg J, Hirsh J, Henderson P, Blajchman MA. Thrombosis in antithrombin Ill-deficient persons. Report of a large kindred and literature review. Ann Intern Med 1992; 116: 754-61
• 3 Broekmans AW, Conard J. Hereditary protein C deficiency. In: Protein C and related proteins Bertina RM. (ed). Edinburgh: Churchill Livingstone; 1988: 160-181
• 4 Engesser L, Broekmans AW, Briet E, Brommer EJP, Bertina RM. Hereditary protein S deficiency: clinical manifestations. Ann Intern Med 1987; 106: 677-682
• 5 Allaart CF, Poort SR, Rosendaal FR, Reitsma PH, Bertina RM, Briet E. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 1993; 341: 134-138
• 6 Rosendaal FR, Heijboer H, Briet E, Buller HR, Brandjes DPM, De Bruin K, Hommes DW, Vandenbroucke JP. Mortality in hereditary antithrombin III deficiency - 1830 to 1989. Lancet 1991; 337: 260-262
• 7 De Stefano V, Leone G. Mortality related to thrombosis in congenital antithrombin III deficiency. Lancet 1991; 337: 847-848
• 8 Tripodi A, Mannucci P. the ad hoc Study Group. A survey of inherited thrombotic syndromes in Italy. Res Clin Lab 1989; 19: 67-74
• 9 Kannel WB, Thom TJ. Incidence, prevalence, and mortality of cardiovascular diseases. In: The heart, 6th edition Hurst JW. (ed). New York: McGraw-Hill; 1986: 557-565
• 10 De Stefano V, Leone G, De Carolis S, Ferrelli R, Di Donfrancesco A, Mo-neta E, Bizzi B. Management of pregnancy in women with antithrombin III congenital defect: report of four cases. Thromb Haemost 1988; 59: 193-196
• 11 Coon WW, Willis PW, Keller JB. Venous thromboembolism and other venous disease in the Tecumseh Community Health Study. Circulation 1973; 48: 839-846
• 12 De Stefano V, Leone G, Micalizzi P, Teofili L, Falappa PG, Pollari G, Bizzi B. Arterial thrombosis as clinical presentation of congenital protein C deficiency. Ann Hematol 1991; 62: 180-183
• 13 Allaart CF, Aronson DC, Ruys T, Rosendaal FR, Van Bockel JH, Bertina RM, Briet E. Hereditary protein S deficiency in young adults with arterial occlusive disease. Thromb Haemost 1990; 64: 206-210
• 14 Launbjerg L, Egeblad H, Heaf J, Nielsen NH, Fugleholm AM, Ladefoged K. Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients. J Int Med 1991; 229: 351-355
• 15 Petitti DB, Strom BL, Melmon KL. Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and haemorrhage. Am J Med 1986; 81: 255-259
• 16 Tengborn L, Bergqvist D. Surgery in patients with congenital antithrombin III deficiency. Acta Chir Scand 1988; 154: 179-183